APGOT-EN6: An interventional phase 3, open label, randomized study to evaluate efficacy and safety of pf-08634404 in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in adult participants with advanced or recurrent mismatch repair proficient endometrial cancer.